

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
5 February 2004 (05.02.2004)

PCT

(10) International Publication Number  
**WO 2004/011678 A1**

- (51) International Patent Classification<sup>7</sup>: C12Q 1/68 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/NL2003/000545
- (22) International Filing Date: 28 July 2003 (28.07.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 1021160 26 July 2002 (26.07.2002) NL
- (71) Applicants (*for all designated States except US*): MULTIGEN INTERNATIONAL B.V. [NL/NL]; Hoogstraat 35, NL-1391 BR Abcoude (NL). VIËTOR, Hendrik, Engelbertus [NL/NL]; Jacob van Gaasbeeklaan 6, NL-1391 CE Abcoude (NL).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): COSSARIZZA, Andrea [IT/IT]; Via Emilia Ovest 192, I-41100 Modena (IT).
- (74) Agent: ALTENBURG, Bernarus, Stephanus, Franciscus; Octrooibureau Los En Stiger B.V., Weteringschans 96, NL-1017 XS Amsterdam (NL).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/011678 A1

(54) Title: METHOD OF DETERMINING THE COPY NUMBER OF A NUCLEOTIDE SEQUENCE

(57) Abstract: The invention relates to a method of determining of accurately determining the copy number of a nucleotide sequence I in a sample using an amplification technique, such as PCR. In addition, a second nucleotide sequence II is also measured and calibration curves for each are made, from which the relative copy number CN can be determined. According to the present invention, accuracy is improved by performing multiple amplifications in a single well using real time PCR.

Method of determining the copy number of a nucleotide sequence

The present invention relates to a method of determining the copy number of a nucleotide sequence I in a sample using an amplification technique, said method comprising the steps of

- 5 1) adding nucleotides, primers, polymerase and any further reagents, if any, required for the amplification technique used to the sample,
- 2) performing one or more amplification cycles to amplify the nucleotide sequence I for which the copy number has to be determined;

10 where the sample contains a chromosomal second nucleotide sequence II, and

- a) the first nucleotide sequence I is amplified,
- b) the second nucleotide sequence II is amplified,

15 c) a third nucleotide sequence I' corresponding to the first nucleotide sequence I and present in a control sample is amplified at various dilutions, and

d) a fourth nucleotide sequence II' corresponding to the second nucleotide sequence II and present in a control sample

20 is amplified at various dilutions,

where the ratio of the concentrations of nucleotide sequence I' and II' is known

where the amplifications of the third and fourth nucleotide sequences I' and II' at various dilutions allows standard curves  $SC_i$  with i being I or II to be made, the concentrations of I and II are determined by using the respective standard curve  $SC_i$ , and the relative concentrations allows the relative copy number CN of sequence I (versus nucleotide sequence II) to be determined using the formula

30

$$CN = \frac{[I]_{scr}}{[II]_{scr}}$$

35 where

CN is the relative copy number of I over II in the sample; [I]<sub>SC<sub>I</sub>'</sub> is the concentration of I determined using standard curve SC<sub>I</sub>'; and

1) [II]<sub>SC<sub>II</sub>'</sub> is the concentration of II determined using standard curve SC<sub>II</sub>'.

Most eukaryotic diploid cells contain two copies of a single gene; one on each chromosome of a pair of chromosomes. The chromosomes of a pair of chromosomes being derived from each parent, the genes may be different and, for example, one of them may result in an abnormal protein. Thus, the number of functional genes is not necessarily 2 in an eukaryote, and can be 1 or even 0. While often genes are present in one copy per chromosome of a particular pair of chromosomes, some genes are present in multiple copies, for example in tandem repeat sequences. Another exception to the general rule of 2 copies per cell is mitochondrial DNA. A cell contains many mitochondria, the number being dependant on the type of cell. But even for a particular cell type, the number of mitochondria may vary. Typical numbers are between 100 and 1000 mitochondria per cell, and each mitochondrion contains several copies of mitochondrial DNA. In addition, the typical copy number is not necessarily equal to larger than 2 per cell. Some nucleotide sequences are very rare among cells (despite being of one and the same subject, such as a human being). This is, for example, after gene rearrangement. This is, for example, the case with antibody producing cells (B-lymphocytes) or receptor-carrying T-lymphocytes. Of a large number of lymphocytes, only a few will contain a particular nucleotide sequence defining the variable region of a particular antibody (or of the T-cell receptor), capable of recognizing a particular antigen. In the art, a need exists to reliably determine the copy number of a nucleotide sequence, which may comprise the nucleotide sequence of a gene or part thereof. A method according to the preamble is known in the art.

A method according to the preamble is known disclosed by Kwok et al in US 5,389,512.

The object of the present invention is to improve

this method for reliably determining the copy number of a nucleotide sequence even if it is present in extreme amounts, such as lots of copies per cell or only few copies per many cells. In addition, an object of the present invention is to 5 provide a method which has reduced sensitivity to the efficiency with which DNA was extracted from the cells containing a nucleotide sequence I for which the copy number has to be determined.

To this end, the method according to the present invention 10 is characterized in that at least one pair of amplification reactions chosen from i) a) and b), and ii) c) and d) is performed in a single container and monitored spectrophotometrically during amplification.

This allows for a more accurate measurement of relative 15 or absolute copy numbers of nucleotide sequence I. Suitable spectrophotometrical methods are known in the art. More specifically, such methods rely on internal probes for real time measurements, for example real time PCR. Internal probes are known in the art, and are disclosed by, for example, Wi- 20 ner et al (Anal. Biochem 270, pp. 41-49 (1999)). Measurements can be done either continuously, or after finishing an amplification cycle. While specific reference is made to standard curves, it goes without saying that this can be done using computational methods without an actual graph being made. 25 Hence, in the present application the phrase "making a standard curve" involves any method using at least two reference points to determine a (relative) concentration. Generally, all amplifications will be performed substantially at the same time. By performing multiple amplifications in one container, the room for error is reduced. The method according 30 to the invention is not only highly accurate, but it is also very efficient if performed for multiple samples. That is, for each nucleotide sequence I for which it is desired to determine the copy number, only a single standard curve  $SC_{II'}$  has to be made. With respect to the term "corresponding" as 35 used in the present invention in conjunction with nucleotide sequences, this is intended to mean that the nucleotide sequences I and I' (and II and II'), or more specifically the

nucleotide sequence of one and the complementary sequence of the other, are capable of hybridizing under stringent conditions. If the sequences I and I' (and II and II') do not have the same length, the shortest of the two is preferably at 5 most 50% shorter, more preferably at most 30% shorter.

The number of amplification cycles are not necessarily the same for I and II, but they are the same for a) I and I' (both n times); and for b) II and II' (both m times), where n and m are the respective number of amplifications, 10 and hence integers, and n and m may or may not be equal.

Douek et al (Nature 396, pp. 690-695 (1998)) describe a method for detecting the products of the rearrangements of T-cell receptors (TREC) using a semi-quantitative assay. For determining the amount of TREC in a given sample, 15 a known amount of a DNA competitor are prepared. Then, an amount of sample DNA containing the nucleotide sequence to be determined are added to the tube. A PCR amplification reaction is carried out in the presence of radiolabeled deoxynucleotide. Subsequently, the resulting amplification products 20 are run on a gel to separate the sample DNA PCR product from the competitor DNA product. After autoradiography, the amount of nucleotide sequence to be determined is calculated using densitometric analysis from the ratio between a band of competitor DNA and a band of the sample DNA. The result is expressed as the number of copies of TREC per microgram total 25 DNA. To achieve an acceptable accuracy, 4 tubes containing scalar amounts of competitor DNA are used, to which fixed amounts of sample DNA are added. The disadvantage of this method is that when DNA is extracted from cells, it must be 30 assumed that this is all the DNA present in the cells. That is, it is assumed that no cell escaped lysis and all DNA present in the cells was extracted and isolated. This is not necessarily the case. Another disadvantage of this method is that it is sensitive to differences in amplification efficiency. 35

According to a preferred embodiment the absolute copy number is determined by multiplying the copy number CN by the absolute copy number of sequence II per cell.

For several nucleotide sequences II the number of copies of per cell is known. An example is, for example, the gene coding for heat shock protein 70, or Fas Ligand (CD178), which are known to be present with two copies per cell (i.e. 5 the absolute copy number of hsp 70 = 2). Many nucleotide sequences of genes are very suitable because they generally are present in a known number of copies in every cell of the species from which the DNA is derived. The efficiency with which DNA material is extracted from the cells is not important 10 (although, in case nucleotide sequence I is on a different molecule as nucleotide sequence II, it is important that they are extracted with the same efficiency). Hence, this embodiment allows determination of the absolute copynumber of the nucleotide sequence I per cell.

15 According to a preferred embodiment, at least one of the third nucleotide sequence I' and fourth nucleotide sequence II' resides on a vector.

In the present application, a vector is understood to be any nucleotide sequence consisting of or containing the 20 nucleotide sequence(s) to be amplified. When present on a vector capable of being replicated in vitro or in vivo, it is easy to obtain that particular nucleotide sequence in desired quantities. It is also very easy to determine the DNA concentration and hence the copy number of the nucleotide sequence 25 per volume. A vector capable of replication or being replicated may be any such vector known in the art, such as a plasmid, a cosmid, a virus etc. If, according to a favourable embodiment, the third nucleotide sequence I' resides on first vector and the fourth nucleotide sequence II' resides on a 30 second vector, the vectors can be used (or mixed) at any desired ratio to accommodate expected differences in copy number in the sample.

It is highly prefered that the third nucleotide sequence I' and fourth nucleotide sequence II' reside on the 35 same vector.

Thus the ratio is constant and exactly known (for example 1:1). This allows for the most accurate measurements possible.

It is possible to subject the vector containing both nucleotide sequence I' and II' to a digestion using one or more restriction enzymes, optionally followed by purification, to yield a linear molecule containing both both nucleotide sequence I' and II', and using this molecule for the amplifications required for the standard curves.

According to a preferred embodiment, at least two different third nucleotide sequences I' for measuring a corresponding number of different first nucleotide sequences I 10 reside on a single vector.

In other words, a single vector, requiring its concentration to be determined only once, can carry multiple third nucleotide sequences I', which allows, for example, the copy numbers of many different genes to be determined.

Preferrably, the sequence of the first nucleotide sequence I is the same as the third nucleotide sequence I'.

This strongly reduces errors due to differences in amplification efficiencies between I and I'. Nevertheless, small differences in nucleotide sequence are generally allowed, although changes at locations where the probe used for detecting the concentration of the nucleotide sequence are best avoided. In other word, it is highly preferred if the probe is a perfect match for the sequence where it is intended to bind.

Similarly, it is preferred that the sequence of the second nucleotide sequence II is the same as the fourth nucleotide sequence II'.

While the present invention is described with reference to DNA, the present invention also applies to the determination of the number of RNA sequences present in a cell.

Use can be made of methods known in the art to multiply RNA, for example by preparing cDNA. This application does not attempt to teach an interested layman how to become a person skilled in the art, for which reason the layman is referred to general text books and in particular to a proper university to learn the required techniques that a person skilled in the art knows how to apply these techniques to work the present invention.

The present invention will now be illustrated with reference to the drawings where

Fig. 1 represents a standard curve for an mtDNA sequence I' (circles) plus data for nucleotide sequence I (squares);

5 Fig. 2 represents a standard curve for a nuclear DNA sequence II' (circles) plus data for nucleotide sequence II (squares);

Fig. 3 represents a standard curve for a nuclear DNA sequence I' (circles) plus data for nucleotide sequence I  
10 (squares);

Fig. 4 represents a standard curve for a nuclear DNA sequence II' (FasL) (circles) plus data for nucleotide sequence II (squares); and

Fig. 5 shows the effect of age on the numbers of copies  
15 of TREC in peripheral lymphocytes (percentage of lymphocyte cells expressing TREC).

The method according to the invention will be illustrated using two Examples. The first relates to the quantitative analysis of mitochondrial DNA (mtDNA) and demonstrates  
20 the technique for determining multiple copies per cell. The second Example demonstrates the quantitative determination of a fractional copy number of a particular nucleotide sequence per cell.

#### EXAMPLE 1

#### 25 MATERIALS AND METHODS

##### Primers

The nucleotide sequence I (mtDNA) was a stretch having a length of 102 nucleotides, and corresponds to part of the enzyme NADH dehydrogenase as coded for by mtDNA. Amplification of nucleotide sequence I was performed using a set of primers, each having a length of 21 nucleotides and synthesized using standard procedures. The sequences of both primers were checked to be unique for human mtDNA using Blast software, through the NCBI site at NIH  
35 (<http://www.ncbi.nlm.nih.gov/blast/>).

The nucleotide sequence II (nuclear DNA) serving as a reference, was a stretch having a length of 104 nucleotides and part of the FasL gene, which comes with two copies per

human cell. Amplification of nucleotide sequence II was performed using a set of primers, each having a length of 21 and 24 nucleotides respectively.

Probes

5 To monitor the progress of amplification, a probe was used for nucleotide sequence I, the probe having a length of 23 nucleotides, having a FAM (carboxy fluorescein) fluorescent probe at the 5' end and a BlackHole Quencher1™ group at the 3' end. This probe, and all others in this application,  
10 was ordered commercially with MWG, Ebersberg, Germany. The sequence of the probe was checked to be unique for human mtDNA using Blast software, through the NCBI site as mentioned above.

The probe used for nucleotide II had a length of 22 nucleotides and contained TexasRed as the fluorescent label and  
15 a BlackHole Quencher2™ group at the 3' end (MWG).

DNA isolation

DNA was isolated from HL60, a promyelocytic leukaemia cell line, using a DNA isolation kit from Qiagen, Hilden,  
20 Germany according to the instructions of the manufacturer.

Control

A vector was constructed, using pGEM-11Z (Promega) containing the sequences I' and II' head to tail, using standard genetic engineering techniques, as all too familiar from Sambrook et al. (Molecular cloning. A lab manual. (1989)) in E. coli. The nucleotide sequences I' and II' were identical to their respective I and II counterparts, and present on the vector in a highly defined 1:1 ratio.

The absolute concentration of the controls was done using limiting dilution assays (Sambrook).  
30

Amplification

Amplification was performed using an iCycler Thermal cycler (BioRad, Hercules, CA, USA) using standard procedures. The amplification is performed in plates having 96 wells.  
35 This instrument allows monitoring of fluorescence in up to 4 different channels. In short, one cycle of denaturation (95 °C for 6 min) was performed, followed by 45 cycles of amplification (94 °C for 30 s, 60 °C for 60 s). The amplification

was performed in a mix that consisted of: Promega PCR buffer 1X (Promega, Madison, WI, USA), 3.0 mM MgCl<sub>2</sub>, 400 pmol of primers for mtDNA, 0.2 mM dNTP and 2 U of *Taq* polymerase (Promega). In accordance with the invention, the amplification for both nucleotide sequences I and II were performed in 5 a single well, and the same is true for nucleotide sequences I' and II' (for determining the standard curves). Data were analysed using the software of the iCycler.

The standard curves were made by introducing a known 10 number of copies of vector per well.

Amplification experiments were performed in triplicate.

#### RESULTS

Fig. 1 shows the standard curve for nucleotide sequence I' and Fig. 2 shows the standard curve for the nucleotide sequence II' based on FasL. Note the excellent correlation coefficients of 0.995 and 0.996 respectively, indicating the excellent accuracy of the method according to the invention. Using these curves, the concentration of nucleotide sequences I and II (shown as squares in Figs. 1 and 2) were determined. 20 As it is known that the nucleotide sequence for FasL (and more specifically for the probe for nucleotide II/II') is present with two copies per cell, the number of copies of nucleotide sequence I per cell is twice as high, i.e. 160.

#### EXAMPLE 2

Basically, the same method was used as described in Example 1, except that the nucleotide sequence I corresponded to part of the sequence of the delta locus of the T-cell receptor. The method was used to determine the number of copies of TREC 30 per cell, in particular peripheral lymphocytes in blood, in three age groups (healthy humans of 20, 60 or 100 years. The number of people were respectively 16 (10), 17 (10), and 21 (17), with the number of women between parentheses)

The standard curves for nucleotide sequence I' and II' 35 are shown in fig. 3 and 4 respectively. The following correlation coefficients obtained were: 0.999 and 0.998.

Fig. 5 shows that the number of copies of TREC decreases with age (averages per age group shown as a horizontal line)

from about 3.2 to 0.1 per 100 cells.

While particularly beneficial for the method according to the present invention in view of the fact that spectrophotometrical methods allow simultaneous detection of 5 multiple labels, it is possible to perform an amplification reaction using any known amplification technique, where the third nucleotide sequence I' and fourth nucleotide sequence II' resides on a single vector and the amplifications of each of I' and II' are performed in separate containers, such as 10 separate wells. The application covers this possibility as well. Such amplification techniques comprise, apart from the ones mentioned above, CP (Cycling Probe Reaction), bDNA (Branched DNA amplification), SSR (Self-Sustained Sequence Replication), SOA (Strand Displacement Amplification), QBR 15 (Q-Beta Replicase), Re-AMP (Formerly RAMP), NASBA (Nucleic Acid Sequence Based Amplification), RCR (Repair Chain Reaction), LCR (Ligase Chain Reaction), TAS (Transorption Based Amplification System), and HCS (amplifies ribosomal RNA).

CLAIMS

1. Method of determining the copy number of a nucleotide sequence I in a sample using an amplification technique, said method comprising the steps of
  - 3) adding nucleotides, primers, polymerase and any further  
5 reagents, if any, required for the amplification technique used to the sample,
  - 4) performing one or more amplification cycles to amplify the nucleotide sequence I for which the copy number has to be determined;
- 10 where the sample contains a chromosomal second nucleotide sequence II, and
  - e) the first nucleotide sequence I is amplified,
  - f) the second nucleotide sequence II is amplified,
  - g) a third nucleotide sequence I' corresponding to the first  
15 nucleotide sequence I and present in a control sample is amplified at various dilutions, and
  - h) a fourth nucleotide sequence II' corresponding to the second nucleotide sequence II and present in a control sample is amplified at various dilutions,
- 20 where the ratio of the concentrations of nucleotide sequence I' and II' is known  
where the amplifications of the third and fourth nucleotide sequences I' and II' at various dilutions allows standard curves  $SC_i$  with i being I or II to be made, the concentrations  
25 of I and II are determined by using the respective standard curve  $SC_i$ , and the relative concentrations allows the relative copy number CN of sequence I (versus nucleotide sequence II) to be determined using the formula
- 30 
$$CN = \frac{[I]_{scr}}{[II]_{scr}}$$
- where  
35 CN is the relative copy number of I over II in the sample;

[I]<sub>scr</sub> is the concentration of I determined using standard curve SC<sub>I'</sub>; and

[II]<sub>scr</sub> is the concentration of II determined using standard curve SC<sub>II'</sub>.

5 **characterized** in that at least one pair of amplification reactions chosen from i) a) and b), and ii) c) and d) is performed in a single container and monitored spectrophotometrically during amplification.

2. Method according to claim 1, **characterized** in  
10 that the absolute copy number is determined by multiplying the copy number CN by the absolute copy number of sequence II per cell.

3. Method according to claim 1 or 2, **characterized** in that the third nucleotide sequence I' and fourth nucleo-  
15 tide sequence II' resides on a single vector.

4. Method according to claim 3, **characterized** in that at least two different third nucleotide sequences I' for measuring a corresponding number of different first nucleotide sequences I reside on a single vector.

20 5. Method according to any of the preceding claims, **characterized** in that the sequence of the first nucleotide sequence I is the same as the third nucleotide sequence I'.

6. Method according to any of the preceding claims, **characterized** in that the sequence of the second nucleotide sequence II is the same as the fourth nucleotide sequence II'.

1/5




FIG. 1

2/5




FIG.2

3/5




FIG.3

4/5





FIG.4

5/5

Fig. 5



# INTERNATIONAL SEARCH REPORT

Internal Application No  
PCT/NL 03/00545

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 959 140 A (BECTON DICKINSON CO) 24 November 1999 (1999-11-24) claims 1-8 ---	1-6
X	EP 1 138 783 A (ROCHE DIAGNOSTICS GMBH) 4 October 2001 (2001-10-04) example 5 ---	1-6
X	US 5 389 512 A (KWOK SHIRLEY Y ET AL) 14 February 1995 (1995-02-14) claims 1-14 ---	1-6
X	US 5 863 736 A (HAALAND PERRY D) 26 January 1999 (1999-01-26) claim 1 ---	1-6 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the International filing date but later than the priority date claimed

\*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed Invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the International search report
23 October 2003	30/10/2003
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentaan 2 NL - 2280 HV Rijswijk Tel: (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Gabriels, J

## INTERNATIONAL SEARCH REPORT

Internal	Application No
PCT/NL 03/00545	

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 100 45 521 A (ROCHE DIAGNOSTICS GMBH) 4 October 2001 (2001-10-04) claim 1 -----	1-6
X	US 5 888 740 A (HAN JIAN) 30 March 1999 (1999-03-30) claims 1-22 -----	1-6
X	WO 99 66075 A (CLEVENGER WILLIAM ;FAHY EOIN D (US); MITOKOR (US); DAVIS ROBERT E) 23 December 1999 (1999-12-23) claim 1 -----	1-6
P,X	WO 02 097124 A (O'SHAUGHNESSY MICHAEL V ;UNIV BRITISH COLUMBIA (CA); COTE HELENE () 5 December 2002 (2002-12-05) the whole document -----	1-6

**INTERNATIONAL SEARCH REPORT**

Intern:	Application No
PCT/NL	03/00545

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0959140	A	24-11-1999	US EP JP	6066458 A 0959140 A2 2000023669 A	23-05-2000 24-11-1999 25-01-2000
EP 1138783	A	04-10-2001	EP EP DE EP JP JP US US AU WO	1138780 A1 1138783 A2 10045521 A1 1138784 A2 2001314194 A 2001314195 A 2003165832 A1 2002058262 A1 5830201 A 0175153 A2	04-10-2001 04-10-2001 04-10-2001 04-10-2001 13-11-2001 13-11-2001 04-09-2003 16-05-2002 15-10-2001 11-10-2001
US 5389512	A	14-02-1995	NONE		
US 5863736	A	26-01-1999	AU AU CA EP JP	738398 B2 6474998 A 2236067 A1 0915169 A2 11004688 A	20-09-2001 26-11-1998 23-11-1998 12-05-1999 12-01-1999
DE 10045521	A	04-10-2001	EP DE EP JP US EP JP US AU WO	1138780 A1 10045521 A1 1138784 A2 2001314194 A 2002058262 A1 1138783 A2 2001314195 A 2003165832 A1 5830201 A 0175153 A2	04-10-2001 04-10-2001 04-10-2001 13-11-2001 16-05-2002 04-10-2001 13-11-2001 04-09-2003 15-10-2001 11-10-2001
US 5888740	A	30-03-1999	WO	9914376 A2	25-03-1999
WO 9966075	A	23-12-1999	US US US AT AU CA DE EP JP WO	2002064773 A1 6218117 B1 6441149 B1 235560 T 4823099 A 2330840 A1 69906284 D1 1086249 A2 2002518023 T 9966075 A2	30-05-2002 17-04-2001 27-08-2002 15-04-2003 05-01-2000 23-12-1999 30-04-2003 28-03-2001 25-06-2002 23-12-1999
WO 02097124	A	05-12-2002	WO CA US	02097124 A1 2416332 A1 2003099933 A1	05-12-2002 05-12-2002 29-05-2003